Close
  Indian J Med Microbiol
 

Figure 3: Body weight of rofecoxib-exposed and control founders in seminatural enclosures over time. (a) No difference in body weight between treatments was detected in females at the model intercept [n = 74, observations = 337 (LMM; t = 0.21, P = 0.83)]. Females gained weight over time (LMM; t = 12.02, P < 0.0001) (b) A trend was detected where rofecoxib-exposed males weighed less than controls at the model intercept [n = 39, observations = 142 (LMM; t = −1.78, P = 0.08)]. Males gained weight over time (LMM; t = 4.54, P < 0.0001) and rofecoxib-exposed males gained more weight over time than controls (LMM: t = 1.98, P < 0.05). Lines connect means and error bars represent standard error

Figure 3: Body weight of rofecoxib-exposed and control founders in seminatural enclosures over time. (a) No difference in body weight between treatments was detected in females at the model intercept [<i>n</i> = 74, observations = 337 (LMM; <i>t</i> = 0.21, <i>P</i> = 0.83)]. Females gained weight over time (LMM; <i>t</i> = 12.02, <i>P</i> < 0.0001) (b) A trend was detected where rofecoxib-exposed males weighed less than controls at the model intercept [<i>n</i> = 39, observations = 142 (LMM; <i>t</i> = −1.78, <i>P</i> = 0.08)]. Males gained weight over time (LMM; <i>t</i> = 4.54, <i>P</i> < 0.0001) and rofecoxib-exposed males gained more weight over time than controls (LMM: <i>t</i> = 1.98, <i>P</i> < 0.05). Lines connect means and error bars represent standard error